查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1402197

全球抗体治疗市场研究报告 - 2023 年至 2030 年行业分析、规模、份额、成长、趋势和预测

Global Antibody Therapeutics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日期: | 出版商: Value Market Research | 英文 221 Pages | 商品交期: 最快1-2个工作天内

价格

全球抗体治疗市场需求预计将从 2022 年的 2,591.4 亿美元增至 2030 年的近 8,043.8 亿美元，2023-2030 年研究期间复合CAGR为 15.21%。

抗体疗法，也称为治疗性抗体或生物药物，是由免疫系统产生的抗体开发的一类药物。这些抗体可以从动物（主要是小鼠或兔子）中改造或衍生，然后进行修饰以用于治疗各种疾病。

市场动态

抗体治疗市场受到多种因素的推动，导致其大幅成长。癌症、自体免疫疾病和传染病等慢性疾病的发生率不断增加，推动了对抗体疗法提供的精确、有针对性的治疗的需求。生物技术的进步，特别是抗体工程和製造方面的进步，带来了更有效、更安全的治疗方法，扩大了在不同医学领域的应用。研发投资，特别是探索新标靶和创新抗体形式，进一步推动市场扩张。向个人化医疗的转变有利于抗体疗法，从而可以为个别患者提供量身定制的治疗。成功的临床试验和监管部门的批准增强了医疗保健专业人员和患者对这些疗法的信心，从而提高了采用率。不断增长的医疗保健支出、行业参与者之间的合作以及各个医学领域基于抗体的治疗范围的不断扩大，共同促进了抗体治疗市场的强劲增长，使这些疗法处于现代医学的前沿。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具还对全球抗体治疗市场的每个细分市场进行了包容性评估。抗体治疗行业的成长和趋势为这项研究提供了整体方法。

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲抗体治疗市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。抗体治疗市场的主要参与者包括罗氏公司（瑞士）、艾伯维公司（美国）、强生公司（美国）、默克公司（德国）、百时美施贵宝公司（美国）、阿斯特捷利康公司（英国）、赛诺菲（法国）、再生元製药公司（美国）、诺华公司（瑞士）、安进公司（美国）、百健公司（美国）。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

  • 报告说明
    • 客观的
    • 目标受众
    • 独特的销售主张 (USP) 和产品
  • 研究范围
  • 研究方法论
    • 市场研究过程
    • 市场研究方法论

第 2 章：执行摘要

  • 市集亮点
  • 全球市场概况

第 3 章：抗体治疗 - 产业分析

  • 简介 - 市场动态
  • 市场驱动因素
  • 市场限制
  • 机会
  • 产业动态
  • 波特五力分析
  • 市场吸引力分析
    • 按格式分類的市场吸引力分析
    • 按疾病领域分類的市场吸引力分析
    • 按给药途径进行的市场吸引力分析
    • 按来源分類的市场吸引力分析
    • 最终用户的市场吸引力分析
    • 市场吸引力分析：按地区

第 4 章：价值链分析

  • 价值链分析
  • 原料分析
    • 原料清单
    • 原料厂商清单
    • 主要原物料价格走势
  • 潜在买家名单
  • 行销管道
    • 直效行销
    • 间接行销
    • 行销通路发展趋势

第 5 章：全球抗体治疗市场分析：依形式

  • 按格式概述
  • 历史和预测数据
  • 按格式分析
  • 单株抗体
  • 多株抗体抗体治疗
  • 双特异性抗体
  • 抗体片段
  • 其他

第 6 章：全球抗体治疗市场分析：依疾病领域

  • 疾病领域概述
  • 历史和预测数据
  • 按疾病领域分析
  • 自体免疫疾病与发炎性疾病
  • 肿瘤学
  • 血液学
  • 传染性疾病
  • 骨科
  • 免疫学
  • 神经病学
  • 其他

第 7 章：全球抗体治疗市场分析：依给药途径

  • 依给药途径概述
  • 历史和预测数据
  • 依给药途径分析
  • 静脉
  • 皮下
  • 其他

第 8 章：全球抗体治疗市场分析：依来源分类

  • 按来源概述
  • 历史和预测数据
  • 按来源分析
  • 人类
  • 人性化
  • 嵌合体
  • 其他

第 9 章：全球抗体治疗市场分析：依最终使用者分类

  • 最终用户概述
  • 历史和预测数据
  • 最终用户分析
  • 医院
  • 长期照护设施
  • 其他

第 10 章：全球抗体治疗市场分析：依地理位置

  • 区域展望
  • 介绍
  • 北美销售分析
    • 概览、历史与预测资料销售分析
    • 北美按细分市场销售分析
    • 北美按国家销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概览、历史与预测资料销售分析
    • 欧洲按细分市场销售分析
    • 欧洲按国家销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 义大利销售分析
    • 俄罗斯销售分析
    • 欧洲其他地区销售分析
  • 亚太地区销售分析
    • 概览、历史与预测资料销售分析
    • 亚太地区按细分市场销售分析
    • 亚太地区国家/地区销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本销售分析
    • 韩国销售分析
    • 澳洲销售分析
    • 东南亚销售分析
    • 亚太地区其他地区销售分析
  • 拉丁美洲销售分析
    • 概览、历史与预测资料销售分析
    • 拉丁美洲按细分市场销售分析
    • 拉丁美洲按国家销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利销售分析
    • 拉丁美洲其他地区销售分析
  • 中东和非洲销售分析
    • 概览、历史与预测资料销售分析
    • 中东和非洲按细分市场销售分析
    • 中东和非洲国家销售分析
    • 沙乌地阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 中东其他地区和非洲销售分析

第 11 章：抗体治疗公司的竞争格局

  • 抗体治疗市场竞争
  • 伙伴关係/协作/协议
  • 併购
  • 新产品发布
  • 其他发展

第 12 章：公司简介

  • 公司股份分析
  • 市场集中度
  • F. Hoffmann-La Roche Ltd. (Switzerland)
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • AbbVie Inc. (US)
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Johnson & Johnson (US)
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Merck KGaA (Germany)
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Bristol-Myers Squibb (US)
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • AstraZeneca (UK)
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Sanofi (France)
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Regeneron Pharmaceuticals Inc. (US)
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Novartis AG (Switzerland)
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Amgen Inc. (US)
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Biogen Inc. (US)
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展

注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内

Product Code: VMR112113173

The global demand for Antibody Therapeutics Market is presumed to reach the market size of nearly USD 804.38 BN by 2030 from USD 259.14 BN in 2022 with a CAGR of 15.21% under the study period 2023 - 2030.

Antibody therapeutics, also known as therapeutic antibodies or biological drugs, are a class of medications developed from antibodies produced by the immune system. These antibodies can be engineered or derived from animals, primarily mice or rabbits, and then modified to be used as treatments for various diseases.

MARKET DYNAMICS

The Antibody therapeutics market is driven by various factors contributing to its substantial growth. Increasing incidences of chronic diseases like cancer, autoimmune disorders, and infectious ailments fuel the demand for precise, targeted treatments that antibody therapies offer. Advancements in biotechnology, particularly in antibody engineering and manufacturing, lead to more effective and safer therapies, expanding their applications across diverse medical fields. Investments in research and development, especially in exploring new targets and innovative antibody formats, further propel market expansion. The shift toward personalized medicine favors antibody therapeutics, allowing tailored treatments for individual patients. Successful clinical trials and regulatory approvals bolster confidence in these therapies among healthcare professionals and patients, driving adoption rates. Rising healthcare expenditure, collaborations among industry players, and the broadening scope of antibody-based treatments in various medical domains collectively contribute to the robust growth of the Antibody therapeutics market, positioning these therapies at the forefront of modern medicine.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of antibody therapeutics. The growth and trends of antibody therapeutics industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the antibody therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Format

  • Monoclonal Antibody
  • Polyclonal Antibody Therapy
  • Bispecific Antibody
  • Antibody Fragment
  • Other

By Disease Areas

  • Autoimmune & Inflammatory Diseases
  • Oncology
  • Hematology
  • Infectious Diseases
  • Osteology
  • Immunology
  • Neurology
  • Other

By Route Of Administration

  • Intravenous
  • Subcutaneous
  • Other

By Source

  • Human
  • Humanized
  • Chimeric
  • Other

By End User

  • Hospitals
  • Long-Term Care Facilities
  • Other

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Antibody Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Antibody Therapeutics market include F. Hoffmann-La Roche Ltd. (Switzerland), AbbVie Inc. (US), Johnson & Johnson (US), Merck KGaA (Germany), Bristol-Myers Squibb (US), AstraZeneca (UK), Sanofi (France), Regeneron Pharmaceuticals, Inc. (US), Novartis AG (Switzerland), Amgen, Inc. (US), Biogen Inc. (US). This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . ANTIBODY THERAPEUTICS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Format
    • 3.7.2 Market Attractiveness Analysis By Disease Areas
    • 3.7.3 Market Attractiveness Analysis By Route Of Administration
    • 3.7.4 Market Attractiveness Analysis By Source
    • 3.7.5 Market Attractiveness Analysis By End User
    • 3.7.6 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL ANTIBODY THERAPEUTICS MARKET ANALYSIS BY FORMAT

  • 5.1 Overview by Format
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Format
  • 5.4 Monoclonal Antibody Historic and Forecast Sales by Regions
  • 5.5 Polyclonal Antibody Therapy Historic and Forecast Sales by Regions
  • 5.6 Bispecific Antibody Historic and Forecast Sales by Regions
  • 5.7 Antibody Fragment Historic and Forecast Sales by Regions
  • 5.8 Other Historic and Forecast Sales by Regions

6 . GLOBAL ANTIBODY THERAPEUTICS MARKET ANALYSIS BY DISEASE AREAS

  • 6.1 Overview by Disease Areas
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Disease Areas
  • 6.4 Autoimmune & Inflammatory Diseases Historic and Forecast Sales by Regions
  • 6.5 Oncology Historic and Forecast Sales by Regions
  • 6.6 Hematology Historic and Forecast Sales by Regions
  • 6.7 Infectious Diseases Historic and Forecast Sales by Regions
  • 6.8 Osteology Historic and Forecast Sales by Regions
  • 6.9 Immunology Historic and Forecast Sales by Regions
  • 6.10. Neurology Historic and Forecast Sales by Regions
  • 6.11 Other Historic and Forecast Sales by Regions

7 . GLOBAL ANTIBODY THERAPEUTICS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 7.1 Overview by Route Of Administration
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Route Of Administration
  • 7.4 Intravenous Historic and Forecast Sales by Regions
  • 7.5 Subcutaneous Historic and Forecast Sales by Regions
  • 7.6 Other Historic and Forecast Sales by Regions

8 . GLOBAL ANTIBODY THERAPEUTICS MARKET ANALYSIS BY SOURCE

  • 8.1 Overview by Source
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by Source
  • 8.4 Human Historic and Forecast Sales by Regions
  • 8.5 Humanized Historic and Forecast Sales by Regions
  • 8.6 Chimeric Historic and Forecast Sales by Regions
  • 8.7 Other Historic and Forecast Sales by Regions

9 . GLOBAL ANTIBODY THERAPEUTICS MARKET ANALYSIS BY END USER

  • 9.1 Overview by End User
  • 9.2 Historical and Forecast Data
  • 9.3 Analysis by End User
  • 9.4 Hospitals Historic and Forecast Sales by Regions
  • 9.5 Long-term Care Facilities Historic and Forecast Sales by Regions
  • 9.6 Other Historic and Forecast Sales by Regions

10 . GLOBAL ANTIBODY THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

  • 10.1. Regional Outlook
  • 10.2. Introduction
  • 10.3. North America Sales Analysis
    • 10.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 10.3.2. North America By Segment Sales Analysis
    • 10.3.3. North America By Country Sales Analysis
    • 10.3.4. United State Sales Analysis
    • 10.3.5. Canada Sales Analysis
    • 10.3.6. Mexico Sales Analysis
  • 10.4. Europe Sales Analysis
    • 10.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 10.4.2. Europe by Segment Sales Analysis
    • 10.4.3. Europe by Country Sales Analysis
    • 10.4.4. United Kingdom Sales Analysis
    • 10.4.5. France Sales Analysis
    • 10.4.6. Germany Sales Analysis
    • 10.4.7. Italy Sales Analysis
    • 10.4.8. Russia Sales Analysis
    • 10.4.9. Rest Of Europe Sales Analysis
  • 10.5. Asia Pacific Sales Analysis
    • 10.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 10.5.2. Asia Pacific by Segment Sales Analysis
    • 10.5.3. Asia Pacific by Country Sales Analysis
    • 10.5.4. China Sales Analysis
    • 10.5.5. India Sales Analysis
    • 10.5.6. Japan Sales Analysis
    • 10.5.7. South Korea Sales Analysis
    • 10.5.8. Australia Sales Analysis
    • 10.5.9. South East Asia Sales Analysis
    • 10.5.10. Rest Of Asia Pacific Sales Analysis
  • 10.6. Latin America Sales Analysis
    • 10.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 10.6.2. Latin America by Segment Sales Analysis
    • 10.6.3. Latin America by Country Sales Analysis
    • 10.6.4. Brazil Sales Analysis
    • 10.6.5. Argentina Sales Analysis
    • 10.6.6. Peru Sales Analysis
    • 10.6.7. Chile Sales Analysis
    • 10.6.8. Rest of Latin America Sales Analysis
  • 10.7. Middle East & Africa Sales Analysis
    • 10.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 10.7.2. Middle East & Africa by Segment Sales Analysis
    • 10.7.3. Middle East & Africa by Country Sales Analysis
    • 10.7.4. Saudi Arabia Sales Analysis
    • 10.7.5. UAE Sales Analysis
    • 10.7.6. Israel Sales Analysis
    • 10.7.7. South Africa Sales Analysis
    • 10.7.8. Rest Of Middle East And Africa Sales Analysis

11 . COMPETITIVE LANDSCAPE OF THE ANTIBODY THERAPEUTICS COMPANIES

  • 11.1. Antibody Therapeutics Market Competition
  • 11.2. Partnership/Collaboration/Agreement
  • 11.3. Merger And Acquisitions
  • 11.4. New Product Launch
  • 11.5. Other Developments

12 . COMPANY PROFILES OF ANTIBODY THERAPEUTICS INDUSTRY

  • 12.1. Company Share Analysis
  • 12.2. Market Concentration Rate
  • 12.3. F. Hoffmann-La Roche Ltd. (Switzerland)
    • 12.3.1. Company Overview
    • 12.3.2. Company Revenue
    • 12.3.3. Products
    • 12.3.4. Recent Developments
  • 12.4. AbbVie Inc. (US)
    • 12.4.1. Company Overview
    • 12.4.2. Company Revenue
    • 12.4.3. Products
    • 12.4.4. Recent Developments
  • 12.5. Johnson & Johnson (US)
    • 12.5.1. Company Overview
    • 12.5.2. Company Revenue
    • 12.5.3. Products
    • 12.5.4. Recent Developments
  • 12.6. Merck KGaA (Germany)
    • 12.6.1. Company Overview
    • 12.6.2. Company Revenue
    • 12.6.3. Products
    • 12.6.4. Recent Developments
  • 12.7. Bristol-Myers Squibb (US)
    • 12.7.1. Company Overview
    • 12.7.2. Company Revenue
    • 12.7.3. Products
    • 12.7.4. Recent Developments
  • 12.8. AstraZeneca (UK)
    • 12.8.1. Company Overview
    • 12.8.2. Company Revenue
    • 12.8.3. Products
    • 12.8.4. Recent Developments
  • 12.9. Sanofi (France)
    • 12.9.1. Company Overview
    • 12.9.2. Company Revenue
    • 12.9.3. Products
    • 12.9.4. Recent Developments
  • 12.10. Regeneron Pharmaceuticals Inc. (US)
    • 12.10.1. Company Overview
    • 12.10.2. Company Revenue
    • 12.10.3. Products
    • 12.10.4. Recent Developments
  • 12.11. Novartis AG (Switzerland)
    • 12.11.1. Company Overview
    • 12.11.2. Company Revenue
    • 12.11.3. Products
    • 12.11.4. Recent Developments
  • 12.12. Amgen Inc. (US)
    • 12.12.1. Company Overview
    • 12.12.2. Company Revenue
    • 12.12.3. Products
    • 12.12.4. Recent Developments
  • 12.13. Biogen Inc. (US)
    • 12.13.1. Company Overview
    • 12.13.2. Company Revenue
    • 12.13.3. Products
    • 12.13.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis by Format (USD MN)
  • Monoclonal Antibody Market Sales by Geography (USD MN)
  • Polyclonal Antibody Therapy Market Sales by Geography (USD MN)
  • Bispecific Antibody Market Sales by Geography (USD MN)
  • Antibody Fragment Market Sales by Geography (USD MN)
  • Other Market Sales by Geography (USD MN)
  • Analysis Market by Disease Areas (USD MN)
  • Autoimmune & Inflammatory Diseases Market Sales by Geography (USD MN)
  • Oncology Market Sales by Geography (USD MN)
  • Hematology Market Sales by Geography (USD MN)
  • Infectious Diseases Market Sales by Geography (USD MN)
  • Osteology Market Sales by Geography (USD MN)
  • Immunology Market Sales by Geography (USD MN)
  • Neurology Market Sales by Geography (USD MN)
  • Other Market Sales by Geography (USD MN)
  • Analysis by Route Of Administration (USD MN)
  • Intravenous Market Sales by Geography (USD MN)
  • Subcutaneous Market Sales by Geography (USD MN)
  • Other Market Sales by Geography (USD MN)
  • Analysis by Source (USD MN)
  • Human Market Sales by Geography (USD MN)
  • Humanized Market Sales by Geography (USD MN)
  • Chimeric Market Sales by Geography (USD MN)
  • Other Market Sales by Geography (USD MN)
  • Analysis by End User (USD MN)
  • Hospitals Market Sales by Geography (USD MN)
  • Long-term Care Facilities Market Sales by Geography (USD MN)
  • Other Market Sales by Geography (USD MN)
  • Global Antibody Therapeutics Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Antibody Therapeutics Report
  • Market Research Process
  • Market Research Methodology
  • Global Antibody Therapeutics Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Format
  • Market Attractiveness Analysis by Disease Areas
  • Market Attractiveness Analysis by Route Of Administration
  • Market Attractiveness Analysis by Source
  • Market Attractiveness Analysis by End User
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Format (USD MN)
  • Monoclonal Antibody Market Sales by Geography (USD MN)
  • Polyclonal Antibody Therapy Market Sales by Geography (USD MN)
  • Bispecific Antibody Market Sales by Geography (USD MN)
  • Antibody Fragment Market Sales by Geography (USD MN)
  • Other Market Sales by Geography (USD MN)
  • Global Market Analysis by Disease Areas (USD MN)
  • Autoimmune & Inflammatory Diseases Market Sales by Geography (USD MN)
  • Oncology Market Sales by Geography (USD MN)
  • Hematology Market Sales by Geography (USD MN)
  • Infectious Diseases Market Sales by Geography (USD MN)
  • Osteology Market Sales by Geography (USD MN)
  • Immunology Market Sales by Geography (USD MN)
  • Neurology Market Sales by Geography (USD MN)
  • Other Market Sales by Geography (USD MN)
  • Global Market Analysis by Route Of Administration (USD MN)
  • Intravenous Market Sales by Geography (USD MN)
  • Subcutaneous Market Sales by Geography (USD MN)
  • Other Market Sales by Geography (USD MN)
  • Global Market Analysis by Source (USD MN)
  • Human Market Sales by Geography (USD MN)
  • Humanized Market Sales by Geography (USD MN)
  • Chimeric Market Sales by Geography (USD MN)
  • Other Market Sales by Geography (USD MN)
  • Global Market Analysis by End User (USD MN)
  • Hospitals Market Sales by Geography (USD MN)
  • Long-term Care Facilities Market Sales by Geography (USD MN)
  • Other Market Sales by Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.